Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01711528 · ClinicalTrials.gov registry record · Phase 1
Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma
A Phase 1 study of Recurrent Plasma Cell Myeloma, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 41
- Enrollment target
- 6
- Study locations
NCT01711528: Completed Phase 1 study of Recurrent Plasma Cell Myeloma, sponsored by National Cancer Institute (NCI).
NCT01711528 is a Phase 1 study of Recurrent Plasma Cell Myeloma that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 41 participants, below the 49-participant average among 23 other Recurrent Plasma Cell Myeloma trials with a reported enrollment target (16% lower). The trial reports 6 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01711528, a Phase 1 study of Recurrent Plasma Cell Myeloma, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 41 participants
- Enrollment target
- 6
- Study locations
Study Summary
This phase I trial studies the side effects and best dose of dinaciclib and bortezomib when given together with dexamethasone in treating patients with multiple myeloma that has returned after a period of improvement. Dinaciclib and bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving dinaciclib and bortezomib together with dexamethasone may kill more cancer cells.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Dexamethasone
- DRUG Bortezomib
- DRUG Dinaciclib
Study Locations (6)
Wisconsin
- University of Wisconsin Hospital and Clinics - Madison
- Aspirus UW Cancer Center - Wisconsin Rapids
Arizona
- Mayo Clinic in Arizona - Scottsdale
Minnesota
- Mayo Clinic - Rochester
Texas
- M D Anderson Cancer Center - Houston
Virginia
- Virginia Commonwealth University/Massey Cancer Center - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2012-12-19 |
| Est. Completion | 2016-11-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01711528
The ClinicalTrials.gov registry entry for NCT01711528 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 49-participant average among 23 other Recurrent Plasma Cell Myeloma trials with a reported enrollment target (16% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Recurrent Plasma Cell Myeloma appearing as the primary indexed condition, and to 4 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT01711528 reports 6 study locations spanning 5 distinct geographic areas - top geographies include Wisconsin, Arizona, Minnesota.
Frequently Asked Questions
What is clinical trial NCT01711528 about?
NCT01711528 is a clinical study titled "Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma". This phase I trial studies the side effects and best dose of dinaciclib and bortezomib when given together with dexamethasone in treating patients with multiple myeloma that has returned after a period of improvement. Dinaciclib and bortezomib may stop the growth of cancer cells by blocking some of ...
What is the current status of trial NCT01711528?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2012-12-19. Estimated completion is 2016-11-22.
What conditions does trial NCT01711528 study?
This clinical trial studies the following conditions: Recurrent Plasma Cell Myeloma.
What interventions are being tested in trial NCT01711528?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Dexamethasone (DRUG), Bortezomib (DRUG), Dinaciclib (DRUG).
Who is sponsoring clinical trial NCT01711528?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01711528 being conducted?
This trial has 6 study locations across Arizona, Minnesota, Texas, Virginia, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Plasma Cell Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
RECRUITING · Phase 1
-
Radioimmunotherapy (111Indium/225Actinium-DOTA-daratumumab) for the Treatment of Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
-
CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma
RECRUITING · Phase 1
-
Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple Myeloma
ACTIVE NOT RECRUITING · Phase 1
-
Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial
ACTIVE NOT RECRUITING · Phase 1
-
Genetically Engineered Cells (MUC1-Activated T-Cells) for the Treatment of MUC1 Positive Recurrent or Refractory Multiple Myeloma
ACTIVE NOT RECRUITING · Phase 1
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.